Source comparison
Thymosin Alpha-1 Chronic Fatigue Protocol Comparison 2026
Standard Therapeutic 1.6mg SC twice weekly 12-16 weeks T-cell modulation + moderate mitochondrial support 60-70% in inflammatory phenotype Gold standard for post-viral fatigue with documented immune activation; well-tolerated with minimal side effects High-Dos
This comparison does not assign a generated winner or score.
- Standard Therapeutic
- 1.6mg SC twice weekly
- 12-16 weeks
- T-cell modulation + moderate mitochondrial support
- 60-70% in inflammatory phenotype
- Gold standard for post-viral fatigue with documented immune activation; well-tolerated with minimal side effects
- High-Dose Intensive
- 2.4-3.0mg SC twice weekly
- 16-20 weeks
- Enhanced mitochondrial gene transcription + maximal Treg expansion
- 50-60% in mixed phenotypes
- Reserved for non-responders to standard dosing; requires closer monitoring for injection site reactions
- Maintenance Protocol
- 0.8-1.6mg SC once weekly
- Ongoing (6+ months)
- Sustained immune homeostasis
- Variable—prevents relapse in prior responders
- Used after initial response to prevent symptom return; cost-effective for long-term management
- Combined Mitochondrial
- 1.6mg SC twice weekly + CoQ10 + L-carnitine + NAD+ precursors
- 16 weeks
- Dual pathway: immune + metabolic restoration
- 70-75% in metabolic phenotype
- Most comprehensive approach; addresses both immune and energy deficits simultaneously